National Bank of Canada’s Bio-Rad Laboratories Class A BIO Stock Holding History

National Bank of Canada’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.1M	Sell	65,000 -25,000	-28%	-$7.09M	0.01%	563
2026 Q1	$25.1M	Buy	+90,000	New	+$25.9M	0.02%	431
2024 Q3	–	Sell	-5,508	Closed	-$1.45M	–	2778
2024 Q2	$1.45M	Buy	5,508 +885	+19%	+$257K	﹤0.01%	989
2024 Q1	$1.3M	Sell	4,623 -11,111	-71%	-$3.65M	﹤0.01%	1084
2023 Q4	$5.04M	Sell	15,734 -2,397	-13%	-$751K	0.01%	765
2023 Q3	$6.44M	Buy	18,131 +884	+5%	+$341K	0.01%	733
2023 Q2	$6.64M	Buy	17,247 +15,760	+1,060%	+$6.41M	0.01%	642
2023 Q1	$712K	Buy	1,487 +863	+138%	+$404K	﹤0.01%	1146
2022 Q4	$262K	Sell	624 -794	-56%	-$320K	﹤0.01%	1410
2022 Q3	$605K	Sell	1,418 -100	-7%	-$49.9K	﹤0.01%	1113
2022 Q2	$762K	Sell	1,518 -6,491	-81%	-$3.38M	﹤0.01%	1094
2022 Q1	$4.51M	Sell	8,009 -3,080	-28%	-$1.86M	0.01%	643
2021 Q4	$8.32M	Buy	+11,089	New	+$8.3M	0.03%	433

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

National Bank of Canada's BIO Position: Q2 2026 in Review

National Bank of Canada reduced its Bio-Rad Laboratories Class A (BIO) stake by 28% in Q2 2026, selling an estimated $7.09M and leaving 65,000 shares worth $19.1M. The position accounts for 0.01% of the portfolio, ranked #563.

National Bank of Canada first reported a position in BIO in Q4 2021 and has held it in 13 quarters since. The position peaked at $25.1M in Q1 2026. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

National Bank of Canada held 65,000 shares of Bio-Rad Laboratories Class A worth $19.1M as of Q2 2026.
National Bank of Canada sold 25,000 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $7.09M.
Bio-Rad Laboratories Class A made up 0.01% of National Bank of Canada's portfolio in Q2 2026, its #563 holding.
National Bank of Canada first reported a position in Bio-Rad Laboratories Class A in Q4 2021 and has held it in 13 quarters since.
National Bank of Canada's Bio-Rad Laboratories Class A position peaked at $25.1M in Q1 2026.
400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.